Patents by Inventor Gene Liau
Gene Liau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240102011Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.Type: ApplicationFiled: October 9, 2023Publication date: March 28, 2024Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
-
Publication number: 20240033378Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.Type: ApplicationFiled: April 13, 2023Publication date: February 1, 2024Inventors: ISABEL AZNAREZ, Enxuan JING, Jacob KACH, Aditya VENKATESH, Juergen SCHARNER, Baruch TICHO, Gene LIAU
-
Patent number: 11814622Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.Type: GrantFiled: April 21, 2023Date of Patent: November 14, 2023Assignee: STOKE THERAPEUTICS, INC.Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
-
Publication number: 20230287410Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.Type: ApplicationFiled: April 30, 2021Publication date: September 14, 2023Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
-
Publication number: 20230250429Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.Type: ApplicationFiled: April 21, 2023Publication date: August 10, 2023Inventors: Isabel Aznarez, Aditya Venkatesh, Gene Liau
-
Publication number: 20230116704Abstract: Alternative splicing events in SCN1A gene can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in SCN1A gene can modulate the expression level of functional proteins in Dravet Syndrome patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition caused by SCN1A, SCN8A or SCN5A protein deficiency.Type: ApplicationFiled: June 3, 2022Publication date: April 13, 2023Inventors: Isabel Aznarez, Zhou Han, Anne Christiansen, Meena Meena, Baruch Ticho, Gene Liau
-
Publication number: 20210268667Abstract: Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency.Type: ApplicationFiled: October 23, 2018Publication date: September 2, 2021Inventors: Isabel AZNAREZ, Enxuan JING, Jacob KACH, Aditya VENKATESH, Juergen SCHARNER, Baruch TICHO, Gene LIAU
-
Publication number: 20070213255Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: ApplicationFiled: October 17, 2006Publication date: September 13, 2007Applicants: Human Genome Sciences, Inc., The American National Red CrossInventors: Gregg Hastings, Gene Liau, Elena Tsifrina
-
Patent number: 7229959Abstract: This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antibody. The composition may be further supplemented with, for example, one or more analgesics, antimicrobial compositions, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.Type: GrantFiled: June 7, 1995Date of Patent: June 12, 2007Assignee: The American National Red CrossInventors: William N. Drohan, Martin J. MacPhee, Hernan Nunez, Gene Liau, Wilson H. Burgess, Thomas Maciag
-
Patent number: 7196054Abstract: This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antimicrobial composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.Type: GrantFiled: June 7, 1995Date of Patent: March 27, 2007Assignee: The American National Red CrossInventors: William N. Drohan, Martin J. MacPhee, Hernan Nunez, Gene Liau, Thomas Maciag, Wilson H. Burgess
-
Patent number: 7189410Abstract: This invention provides a fibrin sealant bandage, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant bandage.Type: GrantFiled: June 7, 1995Date of Patent: March 13, 2007Assignee: The American National Red CrossInventors: William N. Drohan, Martin J. MacPhee, Wilson H. Burgess, Hernan Nunez, Manish Singh, Gene Liau, Thomas Maciag
-
Patent number: 7153670Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: GrantFiled: October 8, 2004Date of Patent: December 26, 2006Assignees: Human Genome Sciences, Inc., The American Red CrossInventors: Gregg A. Hastings, Gene Liau, Elena Tsifrina
-
Publication number: 20060223756Abstract: The present invention relates to peptides that specifically bind to endothelial cells. The peptides can be incorporated into gene delivery vector particles and can also direct therapeutic agents, including proteins such as growth factors and cytokines as well as small molecules. The vector particles, peptides, or small molecules can be used for the treatment of cancer and cardiovascular diseases such as ischemic heart disease, peripheral limb disease, vein graft stenosis and restenosis.Type: ApplicationFiled: December 17, 2003Publication date: October 5, 2006Inventors: Gene Liau, Steingrimur Stefansson, Joseph Su
-
Publication number: 20050239098Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: ApplicationFiled: October 8, 2004Publication date: October 27, 2005Applicants: Human Genome Sciences, Inc., The American Red CrossInventors: Gregg Hastings, Gene Liau, Elena Tsifrina
-
Publication number: 20050202017Abstract: The invention describes assays for the identification of compounds useful for the modulation of angiogenesis. The methods of the invention involve cell-free and cell-based assays that identify compounds which bind to and/or activate or inhibit the activity of HB-954, a G protein-coupled receptor, optionally followed by an in vivo assay of the effect of the compound on angiogenesis. The invention also describes compounds which bind to and/or activate or inhibit the activity of HB-954 as well as pharmaceutical compositions comprising such compounds. In addition, the invention includes nucleic acid molecules comprising a nucleotide sequence encoding all or a portion of HB-954, gene therapy vectors comprising such sequences, polypeptides comprising all or a portion of HB-954 and antibodies directed against HB-954.Type: ApplicationFiled: August 29, 2003Publication date: September 15, 2005Inventors: Katharine Dixon, Gene Liau, Cynthia Serdikoff
-
Patent number: 6872546Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.Type: GrantFiled: December 20, 1999Date of Patent: March 29, 2005Assignees: Human Genome Sciences, Inc., The American Red CrossInventors: Gregg A. Hastings, Gene Liau, Elena Tsifrina
-
Publication number: 20040086487Abstract: A method of inducing blood vessel formation in an animal by administering to the animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof. The polynucleotide may be contained in an appropriate expression vector, such as a viral vector. The delivery of sphingosine kinase through administration of an expression vector which expresses sphingosine kinase provides for the formation of larger blood vessels containing a well defined structure that is supported by mural cells such as pericytes and smooth muscle cells.Type: ApplicationFiled: July 14, 2003Publication date: May 6, 2004Applicant: Novartis AGInventors: Gene Liau, Steingrimur Stefansson, Joseph Su
-
Patent number: RE39192Abstract: This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.Type: GrantFiled: June 20, 2003Date of Patent: July 18, 2006Assignee: American National Red CrossInventors: Martin James MacPhee, William Nash Drohan, Gene Liau, Hernan Nunez, Wilson H. Burgess, Thomas Maciag
-
Patent number: RE39298Abstract: This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.Type: GrantFiled: June 20, 2003Date of Patent: September 19, 2006Assignee: The American National Red CrossInventors: Martin J. MacPhee, William N. Drohan, Gene Liau, Hernan Nunez, Wilson H. Burgess, Thomas Maciag, Manish Singh
-
Patent number: RE39321Abstract: This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.Type: GrantFiled: June 20, 2003Date of Patent: October 3, 2006Assignee: The American National Red CrossInventors: Martin J. MacPhee, William N. Drohan, Gene Liau, Hernan Nunez, Wilson H. Burgess, Jeffrey O. Hollinger, Thomas Maciag